2015
Will this trial change my practice? The Dual Antiplatelet Therapy (DAPT) study - 12 or 30 months of dual antiplatelet therapy after drug-eluting stents.
Grundeken MJ, Lansky A, Tanguay JF, Gershlick A, Baumbach A, Cuisset T. Will this trial change my practice? The Dual Antiplatelet Therapy (DAPT) study - 12 or 30 months of dual antiplatelet therapy after drug-eluting stents. EuroIntervention 2015, 11: 364-5. PMID: 26196757, DOI: 10.4244/eijv11i3a71.Peer-Reviewed Original Research
2011
Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction
Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möeckel M, Stone GW. Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circulation 2011, 123: 1745-1756. PMID: 21482968, DOI: 10.1161/circulationaha.110.981688.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsClopidogrelCoronary RestenosisCoronary ThrombosisDrug Therapy, CombinationDrug-Eluting StentsFemaleHeparinHirudinsHumansMaleMetalsMiddle AgedMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Aggregation InhibitorsPredictive Value of TestsRecombinant ProteinsRisk FactorsTiclopidineTreatment OutcomeTubulin ModulatorsConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionElevation myocardial infarctionPercutaneous coronary interventionBare metal stentsDrug-eluting stentsStent thrombosisCoronary interventionMyocardial infarctionMetal stentsBivalirudin monotherapyOnly bare-metal stentsAcute Myocardial Infarction trialIIb/IIIa inhibitorsClopidogrel loading dosePotent antiplatelet therapyProbable stent thrombosisAcute stent thrombosisMyocardial Infarction trialAcute myocardial infarctionAntithrombin therapyHarmonizing OutcomesAntiplatelet therapyIndependent predictors
2010
Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials
Caixeta A, Lansky AJ, Serruys PW, Hermiller JB, Ruygrok P, Onuma Y, Gordon P, Yaqub M, Miquel-Hebert K, Veldhof S, Sood P, Su X, Jonnavithula L, Sudhir K, Stone GW, Investigators S. Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials. JACC Cardiovascular Interventions 2010, 3: 1220-1228. PMID: 21232715, DOI: 10.1016/j.jcin.2010.07.017.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicAspirinClopidogrelConfidence IntervalsCoronary Artery DiseaseDrug-Eluting StentsEverolimusFemaleFollow-Up StudiesHumansImmunosuppressive AgentsKaplan-Meier EstimateLogistic ModelsMaleMiddle AgedPaclitaxelPlatelet Aggregation InhibitorsProportional Hazards ModelsRandomized Controlled Trials as TopicRiskRisk Reduction BehaviorSirolimusTiclopidineTime FactorsConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsAdverse cardiac eventsTarget vessel failureCardiac eventsMyocardial infarctionSPIRIT IIProbable stent thrombosisAcademic Research ConsortiumEverolimus-eluting stentsVessel failureSignificant reductionLesion revascularizationPES patientsRevascularization eventsIII trialsClinical outcomesEE patientsStent thrombosisPooled analysisCumulative ratePersistent reductionSPIRIT IIIPatientsStents
2009
Gastrointestinal Bleeding in Patients With Acute Coronary Syndromes: Incidence, Predictors, and Clinical Implications Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial
Nikolsky E, Stone GW, Kirtane AJ, Dangas GD, Lansky AJ, McLaurin B, Lincoff AM, Feit F, Moses JW, Fahy M, Manoukian SV, White HD, Ohman EM, Bertrand ME, Cox DA, Mehran R. Gastrointestinal Bleeding in Patients With Acute Coronary Syndromes: Incidence, Predictors, and Clinical Implications Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. Journal Of The American College Of Cardiology 2009, 54: 1293-1302. PMID: 19778672, DOI: 10.1016/j.jacc.2009.07.019.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAge FactorsAgedAngioplasty, Balloon, CoronaryAnticoagulantsClopidogrelCoronary Artery BypassFemaleGastrointestinal HemorrhageHeparinHirudinsHumansIncidenceIschemiaLength of StayMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsRisk AssessmentSex FactorsStentsThrombosisTiclopidineConceptsAcute coronary syndromeGastrointestinal bleedingACUITY trialComposite ischemiaCardiac mortalityCause mortalityCoronary syndromeHigh-risk acute coronary syndromesStudy drug administrationOpen-label usePotential hemorrhagic complicationsST-segment deviationAntiplatelet medicationsBaseline anemiaHemorrhagic complicationsIschemic complicationsIndependent predictorsClinical outcomesMultivariable analysisStent thrombosisMyocardial infarctionSerious conditionPatientsDrug AdministrationOlder ageA Volumetric Intravascular Ultrasound Comparison of Early Drug-Eluting Stent Thrombosis Versus Restenosis
Liu X, Doi H, Maehara A, Mintz GS, de Ribamar Costa J, Sano K, Weisz G, Dangas GD, Lansky AJ, Kreps EM, Collins M, Fahy M, Stone GW, Moses JW, Leon MB, Mehran R. A Volumetric Intravascular Ultrasound Comparison of Early Drug-Eluting Stent Thrombosis Versus Restenosis. JACC Cardiovascular Interventions 2009, 2: 428-434. PMID: 19463466, DOI: 10.1016/j.jcin.2009.01.011.Peer-Reviewed Original ResearchConceptsStent thrombosis groupIntravascular ultrasound findingsMinimum stent areaStent areaThrombosis groupISR groupStent thrombosisUltrasound findingsIntravascular Ultrasound ComparisonProximal stent segmentISR patientsDES thrombosisEdge dissectionStent underexpansionUltrasound comparisonStent fractureThrombosis patientsEarlier drugsStent restenosisThrombosisPatientsStent expansionStent segmentRestenosisLesions
2008
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial
Lansky AJ, Tsuchiya Y, Brener M, Mehran R, Cristea E, Pietras C, Grines CL, Cox DA, Garcia E, Tcheng JE, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Leon MB, Moses J, Stone GW. Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial. Catheterization And Cardiovascular Interventions 2008, 72: 917-924. PMID: 19016469, DOI: 10.1002/ccd.21714.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinClopidogrelCoronary AngiographyDrug Therapy, CombinationEuropeFemaleHemorrhageHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionMyocardial IschemiaPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicRetrospective StudiesRisk AssessmentStentsThrombosisTiclopidineTime FactorsTreatment OutcomeUnited StatesConceptsAcute myocardial infarctionPrimary stentingCADILLAC trialRecurrent ischemiaSevere bleedingMyocardial infarctionEfficacy of clopidogrelMore recurrent ischemiaTIMI 0/1 flowSimilar clinical outcomesTiclopidine treatmentAngiographic characteristicsClopidogrel useIndependent predictorsClinical outcomesMultivariable analysisRandomized trialsStent thrombosisStent implantationOperator's discretionClopidogrelStentingPatientsTiclopidineRelative safetyA Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study
Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB, Schofer J, Buchbinder M, Wijns W, Group C. A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study. Journal Of The American College Of Cardiology 2008, 51: 1543-1552. PMID: 18420096, DOI: 10.1016/j.jacc.2008.01.020.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicChromium AlloysClopidogrelCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDiabetes MellitusFemaleHumansMaleMiddle AgedPaclitaxelPlatelet Aggregation InhibitorsPolymersRiskThromboembolismTiclopidineTime FactorsConceptsPercutaneous coronary interventionTarget vessel revascularizationDrug-eluting stentsMajor adverse cardiac eventsMultivessel percutaneous coronary interventionTaxus drug-eluting stentsMyocardial infarctionAdjudicated deathAdverse cardiac eventsPrimary end pointSegment late lossSingle target lesionPre-specified subgroupsStent thrombosis ratesTreatment of SingleVessel revascularizationCardiac eventsCoronary interventionII studyThrombosis rateAngiographic analysisEpicardial vesselsTarget lesionsLate lossPatients
2002
Late Vascular Response to Repeat Stenting for In-Stent Restenosis With and Without Radiation
Morino Y, Limpijankit T, Honda Y, Lansky AJ, Waksman R, Bonneau HN, Yock PG, Mintz GS, Fitzgerald PJ. Late Vascular Response to Repeat Stenting for In-Stent Restenosis With and Without Radiation. Circulation 2002, 105: 2465-2468. PMID: 12034650, DOI: 10.1161/01.cir.0000018949.39445.40.Peer-Reviewed Original ResearchMeSH KeywordsBlood Vessel Prosthesis ImplantationBrachytherapyCohort StudiesCoronary RestenosisDisease ProgressionDouble-Blind MethodFollow-Up StudiesGamma RaysHumansIridium RadioisotopesPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicRecurrenceReoperationStentsTiclopidineTimeTreatment OutcomeUltrasonography, InterventionalVascular PatencyConceptsLumen volume indexISR lesionsPlacebo patientsLate vascular responseAcute angiographic resultsIntravascular ultrasound analysisIn-Stent RestenosisPlacebo groupAngiographic resultsVascular responsesAdditional lumenNeointimal proliferationStent restenosisIrradiated groupPatientsStent overlapLesionsVolume indexUltrasound analysisSafety of radiationLong-term advantagesStent strutsSignificant decreaseStentingRestenosis
2001
Stent Thrombosis in the Modern Era
Cutlip D, Baim D, Ho K, Popma J, Lansky A, Cohen D, Carrozza J, Chauhan M, Rodriguez O, Kuntz R. Stent Thrombosis in the Modern Era. Circulation 2001, 103: 1967-1971. PMID: 11306525, DOI: 10.1161/01.cir.103.15.1967.Peer-Reviewed Original ResearchMeSH KeywordsAspirinBlood Vessel Prosthesis ImplantationCausalityCoronary DiseaseCoronary ThrombosisEndpoint DeterminationFemaleGraft Occlusion, VascularHumansIncidenceLogistic ModelsMaleMiddle AgedMulticenter Studies as TopicMyocardial RevascularizationOdds RatioPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicSurvival RateTiclopidineTreatment OutcomeConceptsTotal stent lengthStent thrombosisAntiplatelet therapyStent lengthClinical consequencesFinal minimal lumen diameterLumen diameterNative coronary artery lesionsAngiographic stent thrombosisClinical stent thrombosisHigh-pressure deploymentRoutine antiplatelet therapyCoronary artery lesionsIncidence of deathMinimal lumen diameterProcedure-related variablesSecond-generation stentsCoronary stent trialsSerious clinical consequencesFinal lumen diameterNonrandomized registryAntithrombotic regimensArtery lesionsPersistent dissectionMyocardial infarctionCombination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting
Dangas G, Mehran R, Abizaid A, Curry B, Lansky A, Kent K, Pichard A, Satler L, Paliou M, Stone G, Leon M. Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. The American Journal Of Cardiology 2001, 87: 470-472. PMID: 11179539, DOI: 10.1016/s0002-9149(00)01408-9.Peer-Reviewed Original Research